Home > Journals > Minerva Gastroenterology > Past Issues > Minerva Gastroenterologica e Dietologica 2019 September;65(3) > Minerva Gastroenterologica e Dietologica 2019 September;65(3):200-3



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as


ORIGINAL ARTICLE   Free accessfree

Minerva Gastroenterologica e Dietologica 2019 September;65(3):200-3

DOI: 10.23736/S1121-421X.19.02572-8


language: English

Oral iron supplementation with Feralgine® in inflammatory bowel disease: a retrospective observational study

Marta VERNERO 1, 2 , Valentina BOANO 3, Davide G. RIBALDONE 4, Rinaldo PELLICANO 1, Marco ASTEGIANO 1

1 Unit of Gastroenterology, Molinette Hospital, Turin, Italy; 2 First Department of Internal Medicine, University of Pavia, Pavia, Italy; 3 Unit of Gastroenterology, University of Turin, Turin, Italy; 4 Department of Surgical Sciences, University of Turin, Turin, Italy

BACKGROUND: Inflammatory bowel disease (IBD) is a relapsing chronic disease of the gastrointestinal (GI) tract. Among IBD patients, anemia is more frequent than in general population. Recent studies demonstrated a good iron absorption using Feralgine®, a compound of ferrous bysglicinate chelate and alginic acid, oral supplementation with both good compliance rate and efficacy in treating iron deficiency anemia especially due to its high oral bioavailability. In this study we evaluated hemoglobin (Hb) improvement after Feralgine® supplementation in patients with IBD and anemia.
METHODS: This is a retrospective observational study. All data were derived from the patients’ registry of the Inflammatory Bowel Disease Center, San Giovanni Antica Sede-Molinette Hospital, Turin, Italy. All IBD patients suffering from anemia and treated with Feralgine® (Tecnofer Plus), 1 capsule daily, were selected.
RESULTS: Mean Hb value increased from 11 g/dL (95% confidence interval [CI]: 10.72-11.47) to 12.2 g/dL (95% CI: 11.6-12.52, P=0.0001), after three months of Feralgine® supplementation. While 90% of the patients did not report adverse events, 10% experienced dyspepsia and worsening of diarrhea. Only 6% of patients suspended oral iron supplementation due to GI intolerance (adherence rate 94%).
CONCLUSIONS: Oral supplementation with Feralgine® induced a significant improvement in Hb levels, suggesting that in IBD patients with mild or moderate anemia, oral iron supplementation could be considered the first line therapy. We suggest further studies on larger cohorts to assess iron, ferritin and transferrin saturation improvement after this treatment.

KEY WORDS: Inflammatory bowel diseases; Anemia, iron-deficiency; Dietary supplements; Administration, oral

top of page